Dr. Daniel Getts is an energetic executive focused on translating cutting edge scientific breakthroughs into meaningful medical therapies. Dr. Getts uniquely melds his business, pathology and immunology understanding to identify value creating strategic and product development opportunities.
Dr. Getts has over thirty patent/applications and has published his academic work in top tier scientific journals including Nature Biotechnology, the Journal of Experimental Medicine and The Proceedings of The National Academy of Science. In the last 3 years he has obtained in excess of $3 million in grant funding. He serves as Deputy Editor of Cellular Immunology.
Prior to co-founding Cour, Daniel was Director Of Research & Development at Tolera Therapeutics Inc, and was pivotal in moving the lead compound from proof-of-concept into Phase 3. Daniel was a key member of the senior management team leading the company’s R&D efforts and most importantly was instrumental in developing the company’s intellectual property, while supporting the clinical, regulatory & financing programs of the company. In these roles he assisted in raising over $10 million in venture capital and $2 million in non-dilutive capital. Dr Getts holds a Masters of Business (MBA), from Western Michigan University (2012), a Ph.D. in Medicine (2008) and a Bachelor of Medical Science (1st Class Honors, 2004) from the University of Sydney.